T

The University of Texas MD Anderson Cancer Center | Texas Medical Center - Lymphoma and Myeloma Department

Research site
(Unclaimed)
Location
1515 Holcolmbe Blvd, Houston, Texas, United States of America
Site insights

Top conditions

Cancer (84 trials)

Lymphoma (52 trials)

Leukemia (52 trials)

Breast Cancer (35 trials)

Carcinoma (34 trials)

Top treatments

Pembrolizumab
Atezolizumab
Azacitidine
Talazoparib
Nivolumab
Paclitaxel
Binimetinib
Avelumab
Trastuzumab
Cisplatin

Parent organization

This site is a part of The University of Texas MD Anderson Cancer Center

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

187 of 412
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), includ...

Enrolling
SM With an Associated Hematologic Neoplasm (SM-AHN)
Aggressive Systemic Mastocytosis (ASM)
Drug: bezuclastinib

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll...

Enrolling
Metastatic Cancer
Advanced Gastrointestinal Stromal Tumors
Drug: CGT9486
Drug: Sunitinib

This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486...

Enrolling
Mastocytosis
Mastocytosis, Systemic
Drug: Bezuclastinib Tablets (Formulation A)
Drug: Placebo Tablets

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (P...

Active, not recruiting
EGFR T790M
Neoplasms, Nerve Tissue
Drug: osimertinib
Drug: BLU-945

This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressiv...

Enrolling
Relapsed/Refractory Aggressive B-Cell Malignancies
Drug: Bridging Therapy
Biological: ONCT-808

The goal of this clinical research study is to determine whether it is safe and practical to give CK0801 (a Cord blood-derived T-regulatory cell prod...

Active, not recruiting
Bone Marrow Disease
Biological: CK0801

The purpose of this clinical trial is to learn how the experimental medicine maplirpacept (PF-07901801) affects people with various types of blood ca...

Active, not recruiting
Multiple Myeloma
Lymphoma
Drug: Dexamethasone
Drug: Venetoclax

Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with rel...

Enrolling
Relapsed Solid Tumors
Refractory Solid Tumors
Drug: KB-0742

INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of...

Enrolling
Advanced or Metastatic Solid Tumors
Drug: TAC-001

To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer thera...

Active, not recruiting
Advanced or Metastatic Solid Tumors
Drug: Pembrolizumab
Drug: ERAS-601

This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult s...

Active, not recruiting
Advanced or Metastatic Solid Tumors
Drug: Checkpoint Inhibitor, Immune
Drug: MDK-703

The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of u...

Begins enrollment in 1 month
Solid Tumors With FGFR2 Alterations, Adult
Drug: 3HP-2827

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

Enrolling
HER2-positive Endometrial Cancer
HER2-positive Colorectal Cancer
Drug: BDC-1001
Drug: Nivolumab

The purpose of this dose escalation study is to evaluate the safety profile of escalating doses and dose schedules of NXP900.

Enrolling
Advanced Solid Tumor
Drug: NXP900

This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and p...

Enrolling
Solid Tumor
Drug: SAIL66
Drug: Tocilizumab

This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 & HB-202 two-vecto...

Enrolling
HPV-Related Squamous Cell Carcinoma
Drug: HB-202 intravenous administration alternating with HB-201 intravenous administration.
Drug: HB-201 intravenous administration + standard of care regimen including pembrolizumab.

This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety,...

Active, not recruiting
Breast Cancer
Non-hodgkin Lymphoma
Drug: CYT-0851
Drug: CYT-0851 in combination with capecitabine

This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib,...

Enrolling
Melanoma
Advanced Solid Tumor
Drug: DCC-3116
Drug: Trametinib

This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in com...

Enrolling
Solid Tumor
Advanced Solid Tumor
Drug: MRTX849
Drug: MRTX0902

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in p...

Enrolling
Chronic Myeloid Leukemia
Drug: ELVN-001

Trial sponsors

Pfizer logo

Pfizer (44 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems